Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate argenx SE before investing.

In this article, we go over a few key elements for understanding argenx SE’s stock price such as:

• argenx SE’s current stock price and volume
• Why argenx SE’s stock price changed recently
• Upgrades and downgrades for ARGX from analysts
• ARGX’s stock price momentum as measured by its relative strength

About argenx SE (ARGX)

Before we jump into argenx SE’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Want to learn more about argenx SE’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about argenx SE.

argenx SE’s Stock Price as of Market Close

As of July 31, 2026, 2:16 PM, CST, argenx SE’s stock price was $856.560.

argenx SE is down 1.84% from its previous closing price of $872.580.

During the last market session, argenx SE’s stock traded between $846.155 and $873.080. Currently, there are approximately 62.31 million shares outstanding for argenx SE.

argenx SE’s price-earnings (P/E) ratio is currently at 33.3, which is high compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

argenx SE Stock Price History

argenx SE’s (ARGX) price is currently down 7.68% so far this month.

During the month of July, argenx SE’s stock price has reached a high of $953.580 and a low of $843.585.

Over the last year, argenx SE has hit prices as high as $953.580 and as low as $631.470. Year to date, argenx SE’s stock is up 1.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused argenx SE Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded argenx SE’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate argenx SE’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on argenx SE’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

argenx SE’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about argenx SE (ARGX) by visiting AAII Stock Evaluator.

Relative Price Strength of argenx SE

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, argenx SE has a weighted four-quarter relative price strength of 6.94%, which translates to a Momentum Score of 74 and is considered to be Strong.

Want to learn more about how argenx SE is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

argenx SE Stock Price: Bottom Line

As of July 31, 2026, argenx SE’s stock price is $856.560, which is down 1.84% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like argenx SE stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.